Welcome to our dedicated page for Akebia Therapeut SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akebia Therapeutics, Inc. (Nasdaq: AKBA) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering investors structured access to its official communications. As a biopharmaceutical company focused on kidney disease, Akebia uses filings such as Forms 8-K, 10-K, and 10-Q to report material agreements, financial performance, and key clinical and regulatory developments related to products like Vafseo (vadadustat) and Auryxia (ferric citrate), as well as its rare kidney disease pipeline.
Recent 8-K filings illustrate the type of information investors can expect. One filing describes an amendment to Akebia’s License Agreement with MEDICE Arzneimittel Putter GmbH & Co. KG, under which Akebia supplies vadadustat drug substance and Medice has rights to manufacture Vafseo tablets for Europe and certain other countries, with resulting know-how and patent rights owned by Akebia. Other 8-Ks furnish quarterly financial results, highlight business updates such as Vafseo commercialization metrics, and disclose regulatory decisions, including Akebia’s announcement that it does not plan to initiate the VALOR trial and does not expect to pursue a broad label for Vafseo in CKD patients not on dialysis.
Through this page, users can review annual reports on Form 10-K for comprehensive discussions of risk factors, product portfolios, and strategy; quarterly reports on Form 10-Q for interim financial and operational updates; and current reports on Form 8-K for material events. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers. Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight material changes, and help readers quickly understand how new disclosures may relate to Akebia’s kidney disease programs and overall business.
Akebia Therapeutics reported an equity grant to SVP and Chief Accounting Officer Richard C. Malabre. On January 30, 2026, he received 79,000 restricted stock units and 119,000 stock options with a $1.41 exercise price, issued under Akebia’s 2023 Stock Incentive Plan.
The restricted stock units vest in three equal annual installments on the first, second and third anniversaries of the grant date, assuming continued service. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal quarterly installments. After this grant, Malabre beneficially owns 348,914 shares of common stock, including shares bought through the company’s employee stock purchase plan, and holds 119,000 stock options.
Akebia Therapeutics reported an equity compensation grant to its senior executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer. On January 30, 2026, he received 204,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 707,586 shares.
He was also granted stock options covering 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. One third of the restricted stock units vest on each of the first three anniversaries of the grant date, while 25% of the options vest on the first anniversary and the remaining 75% vest in equal quarterly installments over the following three years, in each case contingent on continued service.
Akebia Therapeutics CEO and President John P. Butler reported new equity awards on January 30, 2026. He received 743,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 3,463,849 shares.
He was also granted a stock option for 1,115,000 shares at an exercise price of $1.41 per share, expiring on 01/30/2036. These options vest over four years, while the restricted stock units vest in three equal annual installments, both subject to his continued service. An additional 159,928 shares are held indirectly through the Dorothy Butler Revocable Trust.
Akebia Therapeutics executive Carolyn M. Rucci, SVP and Chief Legal Officer, filed an initial ownership report showing her equity position in the company. She reports beneficial ownership of multiple blocks of Akebia common stock, including 171,816 shares held directly and additional shares linked to restricted stock unit grants.
The filing also lists several employee stock options to buy Akebia common stock, with exercise prices ranging from $0.63 to $2.88 per share and expiration dates between 2031 and 2035. These options generally vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments, subject to continued service.
A shareholder of Akebia Therapeutics, Inc. has filed a notice of proposed sale of 34951 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq. The filing lists an aggregate market value of 48739.00 for these shares.
The shares are part of a much larger base of 265365993 shares outstanding. They were acquired as restricted stock on 01/31/2026, with a listed payment date of 02/02/2026. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Akebia Therapeutics, Inc. shareholder plans to sell common stock under Rule 144. The notice covers the proposed sale of 84,829 shares of Akebia common stock, with an aggregate market value of $118,294.00. The shares are to be sold through Morgan Stanley Smith Barney LLC on the Nasdaq market, with an approximate sale date of February 2, 2026.
The securities were acquired as restricted stock from Akebia Therapeutics, Inc. on January 31, 2026, with 84,829 shares granted and payment noted as non-cash. The filing also notes total shares outstanding of 265,365,993 common shares, providing context for the size of the proposed sale.
A shareholder of Akebia Therapeutics, Inc. filed a Rule 144 notice to sell 67,658 shares of common stock on the Nasdaq through Morgan Stanley Smith Barney LLC, for an aggregate market value of $94,349. These shares were acquired as restricted stock from Akebia on January 31, 2026, with payment dated February 2, 2026. The filing notes that 265,365,993 shares of the issuer’s common stock are outstanding.
Akebia Therapeutics insider-related holders filed a notice to sell up to 341,305 shares of common stock under Rule 144. The proposed sale has an aggregate market value of $475,950.00 and is expected to be executed through Morgan Stanley Smith Barney LLC on Nasdaq around 02/02/2026.
The filing notes that these shares are common stock and indicates that 265,365,993 shares of this class were outstanding, providing scale for the planned sale. The shares to be sold were acquired as restricted stock from Akebia Therapeutics, Inc. on 01/31/2026.
An unnamed holder of Akebia Therapeutics, Inc. common stock has filed a notice to sell 69772 shares under Rule 144. The planned sale, with an aggregate market value of 97297.00, is to be executed through Morgan Stanley Smith Barney LLC on the Nasdaq around 02/02/2026. The securities are restricted stock originally acquired from Akebia on 01/31/2026, and the filing notes that total common shares outstanding are 265365993.
Akebia Therapeutics entered into a long-term lease to relocate its corporate headquarters to new office and lab space in Waltham, Massachusetts. The lease covers approximately 43,474 square feet and includes an initial annual rent of $898,317 for the office area and $1,046,920 for the lab area, subject to scheduled yearly increases. The initial term runs 84 months from the office commencement date, with a security deposit of $810,515 provided via letter of credit and an option for a five-year extension.
Akebia also approved amended executive severance agreements for its CEO, John P. Butler, and CFO, Erik J. Ostrowski, to better align with market practices. These agreements provide specified periods of salary continuation, bonus payments, COBRA premium reimbursements, and accelerated vesting of equity awards upon certain terminations, particularly in connection with a change in control, contingent on a release of claims and ongoing restrictive covenants.